219 related articles for article (PubMed ID: 23813043)
21. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
22. Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
Ruatta F; Derosa L; Escudier B; Colomba E; Guida A; Baciarello G; Loriot Y; Fizazi K; Albiges L
Eur J Cancer; 2019 Jan; 107():79-85. PubMed ID: 30551078
[TBL] [Abstract][Full Text] [Related]
23. The association of hematologic parameters on the prognosis of patients with metastatic renal cell carcinoma.
Dirican A; Kucukzeybek Y; Somali I; Erten C; Demir L; Can A; Bahriye Payzin K; Vedat Bayoglu I; Akyol M; Koseoglu M; Alacacioglu A; Oktay Tarhan M
J BUON; 2013; 18(2):413-9. PubMed ID: 23818354
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil number after interferon-alfa treatment is an independent predictive marker of overall survival in metastatic renal cell carcinoma.
Azuma T; Matayoshi Y; Nagase Y; Oshi M
Clin Genitourin Cancer; 2012 Sep; 10(3):180-4. PubMed ID: 22608529
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy.
Tamura K; Matsushita Y; Watanabe H; Motoyama D; Ito T; Sugiyama T; Otsuka A; Miyake H
Urol Oncol; 2020 Jan; 38(1):6.e9-6.e16. PubMed ID: 31400935
[TBL] [Abstract][Full Text] [Related]
26. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
28. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
29. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
[TBL] [Abstract][Full Text] [Related]
30. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
Richey SL; Culp SH; Jonasch E; Corn PG; Pagliaro LC; Tamboli P; Patel KK; Matin SF; Wood CG; Tannir NM
Ann Oncol; 2011 May; 22(5):1048-1053. PubMed ID: 21115604
[TBL] [Abstract][Full Text] [Related]
31. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.
Goebell PJ; Müller L; Hübner A; Harich HD; Boller E; Koska M; Jänicke M; Marschner N;
Urol Oncol; 2018 Oct; 36(10):470.e1-470.e9. PubMed ID: 30131294
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
34. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Heng DY; Xie W; Regan MM; Warren MA; Golshayan AR; Sahi C; Eigl BJ; Ruether JD; Cheng T; North S; Venner P; Knox JJ; Chi KN; Kollmannsberger C; McDermott DF; Oh WK; Atkins MB; Bukowski RM; Rini BI; Choueiri TK
J Clin Oncol; 2009 Dec; 27(34):5794-9. PubMed ID: 19826129
[TBL] [Abstract][Full Text] [Related]
36. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
Pal SK; Nelson RA; Vogelzang N
PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
[TBL] [Abstract][Full Text] [Related]
37. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.
Tatsugami K; Shinohara N; Kondo T; Yamasaki T; Eto M; Tsushima T; Terachi T; Naito S;
Int J Urol; 2015 Aug; 22(8):736-40. PubMed ID: 25988793
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
39. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
[TBL] [Abstract][Full Text] [Related]
40. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
